A Phase I, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability and Pharmacokinetics of NXL104 Alone and in Combination With Ceftazidime Administered as Single and Repeated Intravenous Doses in Healthy Japanese Subjects.

Trial Profile

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability and Pharmacokinetics of NXL104 Alone and in Combination With Ceftazidime Administered as Single and Repeated Intravenous Doses in Healthy Japanese Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Jul 2015

At a glance

  • Drugs Avibactam; Avibactam/ceftazidime
  • Indications Gram-negative infections; Intra-abdominal infections; Urinary tract infections
  • Focus Adverse reactions
  • Most Recent Events

    • 16 May 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 25 Feb 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 15 Feb 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top